Alpha Therapy Laboratories

Alpha Therapy Laboratories is a biotechnology company focused on the development of next-generation targeted alpha therapies (TAT) for the treatment of various cancers. The company leverages high-energy alpha-emitting isotopes, such as Actinium-225, conjugated to precision-targeting vectors to deliver potent radiation directly to tumor cells while sparing healthy tissue. Their pipeline primarily targets high-unmet-need oncology indications, including metastatic castration-resistant prostate cancer and other solid tumors. By optimizing the chelator and linker technologies, Alpha Therapy Laboratories aims to improve the stability and efficacy of radiopharmaceutical conjugates.